Is Circulation a Good Journal in 2026? An Honest Assessment

Circulation has an impact factor of 38.6. It's been published by the American Heart Association since 1950 and is the most-cited general cardiovascular journal in the world. It accepts around 8% of submissions, desk-rejects the majority, and has a specific editorial identity that makes it different from JACC in ways researchers often get wrong.

What Circulation Actually Publishes

Circulation covers the full cardiovascular spectrum: basic science, translational research, clinical trials, and epidemiology, all within cardiovascular medicine.

Core content areas:

• Large, practice-changing cardiovascular clinical trials
• Mechanistic cardiovascular research with direct clinical or therapeutic implications
• Cardiovascular epidemiology with major public health implications
• Novel cardiovascular pathophysiology discoveries
• Guidelines and scientific statements from AHA expert panels

The AHA identity shapes editorial priorities. Conditions that AHA prioritizes - heart failure, coronary artery disease, hypertension, arrhythmia, stroke, cardiovascular prevention - get more editorial attention than niche cardiovascular subspecialties.

The IF of 37.8 in Context

Circulation at 38.6 sits at the top of the cardiovascular-specific journal tier. Its nearest competitor is European Heart Journal (35.6). Both are strong first targets for high-impact cardiovascular work that isn't going directly to NEJM or Lancet.

Note the distinction: Circulation Research (IF 16.2) is the basic science companion journal from AHA. If your paper is primarily basic cardiovascular science, Circulation Research may be a better fit than the flagship Circulation.

What Gets Desk Rejected

Cardiovascular subspecialty scope only. Research relevant primarily to electrophysiologists, structural interventionalists, or a single subspecialty without broader cardiovascular relevance gets redirected to specialty titles.

Incremental clinical evidence. A trial that confirms existing practice with better power or a cleaner population is often not enough. Circulation wants findings that change practice or establish new evidence standards.

Basic science without clinical path. Purely preclinical work without a translational hook is more appropriate for Circulation Research or field-specific journals.

Single-center studies claiming broad generalizability. Circulation reviewers are skeptical of single-center or small multi-center data presented as definitive.

Methodology papers. Technique papers belong in specialist imaging or device journals, not Circulation flagship.

Circulation vs JACC vs European Heart Journal

These three journals are the primary choices for top cardiovascular research that doesn't go to NEJM or Lancet.

Circulation (IF 38.6): Broadest cardiovascular scope, AHA affiliation, strongest in North America. Best for research with broad cardiovascular relevance across basic, translational, and clinical domains.

JACC (IF 22.3): Clinical cardiology focus. The primary home of cardiovascular clinical practice. Lower IF but the JACC network (JACC: Cardiovascular Interventions, JACC: Heart Failure, etc.) provides strong specialty routing options.

European Heart Journal (IF 35.6): ESC affiliation, European focus, comparable IF to Circulation. Often the better first target for European research groups or papers with strong European population data.

For most cardiovascular researchers in North America: Circulation first if the finding is broadly significant, JACC if it's clinically strong but more practice-specific, EHJ if there's a European angle.

Who Does Well at Circulation

Published output patterns:

• Cardiovascular clinical trialists with multicenter, practice-changing results
• Translational cardiovascular researchers connecting mechanism to clinical insight in human heart failure, CAD, or arrhythmia
• Cardiovascular epidemiologists with large cohort findings on risk factors, outcomes, or prevention
• Basic cardiovascular scientists with findings on heart development, regeneration, or fundamental cardiovascular mechanisms with clear clinical connections
• AHA guideline and scientific statement authors (by invitation)

The Circulation Family

Like most flagship journals, Circulation sits at the top of a family:

• Circulation Research (IF 16.2): Basic and translational cardiovascular science
• JACC and its subspecialty journals: clinical cardiology
• Circulation: Cardiovascular Imaging, Interventions, Genetics, Quality: Specialty titles for domain-specific work

Understanding this hierarchy before submission prevents the common mistake of targeting the flagship for work that belongs at a specialty title.

Submission Practicalities

Circulation uses Editorial Manager through the AHA. Key specifics:

Article types. Original Research, Research Letters (brief important findings), Reviews (mostly solicited), and AHA Scientific Statements (by invitation). Original Research is the primary submission track.

Word limits. Original Research: typically 4,000-5,000 words main text. Structured abstract: 300 words.

AHA membership. Not required for submission, but AHA members receive APC discounts on open access publication.

Timeline. Desk rejection: 7-14 days. Peer review first decision: 6-10 weeks.

How Circulation Compares to Similar Journals

The cardiovascular journal field is competitive. Here's where Circulation sits relative to its closest peers:

European Heart Journal has a slightly higher IF, but Circulation carries stronger weight in North America and among interventional cardiologists. JACC sits just below Circulation but accepts a wider range of clinical study designs.

For most US-based cardiovascular researchers, Circulation and JACC are the two primary targets for high-impact clinical work. Which one to target depends on the nature of the study: Circulation publishes landmark trials and broad mechanistic work; JACC skews more toward interventional and imaging studies.

What Circulation Editors Actually Look For

The desk rejection at Circulation comes fast , usually within two weeks. The editors are screening for two things primarily: clinical significance and study design rigor.

Clinical significance means the findings change how cardiologists manage a common condition, or substantially revise understanding of a major cardiovascular mechanism. A study that's well-executed but addresses a niche question in a specialty population typically gets redirected to a more focused journal.

Study design rigor means randomized trials or prospective cohort studies with well-defined endpoints. Retrospective analyses and case series are accepted but held to a higher bar for novelty and clinical implication.

The cover letter matters at Circulation more than at some other journals. Framing the clinical impact clearly , specifically, which patients this affects and how , is worth the effort before you submit.

AHA Journals: Where Does Each Paper Belong?

The American Heart Association publishes a family of journals across different tiers. Understanding where each paper belongs saves time and avoids unnecessary rejection cycles:

• Circulation: Flagship , landmark trials, major mechanistic discoveries
• Circulation Research: Translational and basic science with clinical implications
• Circulation: Heart Failure: Heart failure-specific clinical research
• JAHA: Open access for solid cardiovascular research that doesn't meet the flagship bar
• Hypertension: Blood pressure and hypertension-specific work

If your cardiovascular paper is strong but doesn't quite clear Circulation's bar for scope and impact, JAHA is the most appropriate next target , not a step down in prestige for the right paper, but a more accessible venue with a lower desk rejection rate.

When to Target a Lower-Tier Cardiovascular Journal Instead

Not every strong cardiovascular paper belongs in Circulation. If your study is well-executed but doesn't meet the scope or impact threshold, submitting to Circulation wastes time , the desk rejection comes in two weeks and you're back to the drawing board.

The AHA journal family gives you a natural progression: Circulation for landmark work, Circulation Research for mechanistic translational studies, JAHA for solid clinical work that doesn't clear Circulation's bar. Getting the tier right on the first submission is faster than chasing the wrong target and stepping down after a rejection.

For authors in cardiovascular medicine deciding between Circulation and JAHA, the rule of thumb is: if your study changes what cardiologists do with their next patient, it belongs in Circulation. If it adds meaningfully to the evidence base without immediately changing practice, JAHA is the right call. Both serve the field well , the distinction is about matching your paper's actual contribution to the right editorial bar.

For most US-based cardiovascular researchers, Circulation and the European Heart Journal represent the two flagship options worth preparing a submission for carefully. Which one to target depends primarily on where the primary audience for your findings sits.

The Bottom Line

Circulation is a top-tier cardiovascular journal with a specific AHA identity and broad scope across basic, translational, and clinical cardiovascular research. It's the right first target when your cardiovascular finding is broadly significant and well-validated.

For practice-level clinical cardiology work, JACC may be a better probability-adjusted first target. For basic cardiovascular science, Circulation Research is the right home. For European groups, EHJ is a comparable alternative.

Sources

• Circulation for authors: ahajournals.org/journal/circ
• American Heart Association journal portfolio: ahajournals.org
• Clarivate Journal Citation Reports 2025
• Full Circulation journal profile

See also

• Is NEJM a good journal?
• Is The Lancet a good journal?
• Is JAMA a good journal?